Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Eyepoint Pharmaceuticals Inc (EYPT)

Eyepoint Pharmaceuticals Inc (EYPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares GlobeNewswire - Thu Oct 31, 3:00PM CDT

EYPT : 12.06 (+2.55%)
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering GlobeNewswire - Tue Oct 29, 8:47PM CDT

EYPT : 12.06 (+2.55%)
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire - Mon Oct 28, 4:14PM CDT

EYPT : 12.06 (+2.55%)
EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema GlobeNewswire - Mon Oct 28, 6:00AM CDT

EYPT : 12.06 (+2.55%)
EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration GlobeNewswire - Thu Oct 24, 6:00AM CDT

EYPT : 12.06 (+2.55%)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire - Wed Oct 16, 6:00AM CDT

EYPT : 12.06 (+2.55%)
EyePoint Pharmaceuticals: Q2 Earnings Snapshot AP - Wed Aug 7, 6:09AM CDT

EyePoint Pharmaceuticals: Q2 Earnings Snapshot

EYPT : 12.06 (+2.55%)
Charts, tickers, traders - Stock chart on computer screen by M_ via Unsplash
2 Small-Cap Stocks Under $20 With Over 220% Upside Potential Barchart - Sun Aug 4, 8:45AM CDT

Wall Street is forecasting multibagger returns from these two small-cap biotech stocks over the next year.

LLY : 818.93 (-1.30%)
NVO : 111.94 (-0.01%)
MRK : 101.88 (-0.43%)
EYPT : 12.06 (+2.55%)
ALT : 6.74 (unch)
Wall Street - NY Stock Exchange -mHdATQY9fIU-unsplash
Stocks Settle Higher on Solid Earnings and Fed Rate Cut Optimism Barchart - Mon May 6, 3:57PM CDT

The S&P 500 Index ($SPX ) (SPY ) Monday closed up +1.03%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.13%. US stock indexes...

$SPX : 5,728.80 (+0.41%)
SPY : 571.04 (+0.42%)
$DOWI : 42,052.19 (+0.69%)
DIA : 420.42 (+0.66%)
$IUXX : 20,033.14 (+0.72%)
QQQ : 487.43 (+0.74%)
ZNZ24 : 110-010s (-0.40%)
SMCI : 26.05 (-10.51%)
NVDA : 135.40 (+1.99%)
AMD : 141.86 (-1.53%)
KLAC : 669.38 (+0.47%)
AVGO : 168.92 (-0.50%)
Wall Street - shutterstock_181756625
Stocks Climb on Strength in Chips Stocks and Fed Rate Cut Optimism Barchart - Mon May 6, 10:31AM CDT

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.61%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.60%. US stock indexes this morning...

$SPX : 5,728.80 (+0.41%)
SPY : 571.04 (+0.42%)
$DOWI : 42,052.19 (+0.69%)
DIA : 420.42 (+0.66%)
$IUXX : 20,033.14 (+0.72%)
QQQ : 487.43 (+0.74%)
ZNZ24 : 110-010s (-0.40%)
MU : 99.73 (+0.08%)
NVDA : 135.40 (+1.99%)
AMD : 141.86 (-1.53%)
GFS : 36.63 (+0.36%)
KLAC : 669.38 (+0.47%)

Barchart Exclusives

Thanks to Wall Street, Novo Nordisk Stock is Now a Buy Barchart - Sat Nov 2, 10:15AM CDT
Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a valuation a third cheaper than competitor, Eli Lilly. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot